Lamiprex 250 Tablet ER contains Divalproex sodium 250 mg, an extended-release formulation used primarily in the management of epilepsy, bipolar disorder, and migraine prophylaxis. Divalproex acts by increasing brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby stabilizing neuronal activity and reducing seizure frequency. The extended-release formulation ensures a steady plasma concentration, enhancing therapeutic efficacy and improving patient compliance by allowing once or twice daily dosing. Lamiprex 250 is indicated for the treatment of complex partial seizures, absence seizures, and as a mood stabilizer in bipolar disorder to control manic episodes. Additionally, it is employed in the prevention of migraine headaches in adults. The medication should be administered under medical supervision with dosage adjustments based on clinical response and tolerability. Common adverse effects include gastrointestinal disturbances, weight gain, tremor, and sedation, while serious risks involve hepatotoxicity, pancreatitis, and teratogenicity, necessitating regular monitoring of liver function tests, complete blood counts, and serum valproate levels. Lamiprex 250 is contraindicated in patients with hepatic impairment, mitochondrial disorders, or hypersensitivity to valproate compounds. Caution is advised during pregnancy and lactation. This medication should be used as part of a comprehensive treatment plan tailored to individual patient needs.